Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration

Neuropsychopharmacology

Volumn 32, Issue 10, 2007, Pages 2238-2247

  Wee, Sunmee ^a   Wang, Zhixia ^b   Woolverton, William L ^b   Pulvirenti, Luigi ^a   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine receptor partial agonist; Escalation; Methamphetamine; Rats; Self administration

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG SELF ADMINISTRATION; IN VITRO STUDY; LONG TERM CARE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN CHEMISTRY; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; MALE; METHAMPHETAMINE; NUCLEUS ACCUMBENS; PIPERAZINES; QUINOLONES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; SELF ADMINISTRATION;

EID: 34548671926     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301353     Document Type: Article

References (53)

1. Ahmed SH, Kenny PJ, Koob GF, Markou A (2002). Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci 5: 625-626.
2. Ahmed SH, Koob GF (1998). Transition from moderate to excessive drug intake: change in hedonic set point. Science 282: 298-300.
3. Ahmed SH, Koob GF (1999). Long-lasting increase in the set point for cocaine self-administration after escalation in rats. Psychopharmacology 146: 303-312.
4. Ahmed SH, Koob GF (2004a). Changes in response to a dopamine receptor antagonist in rats with escalating cocaine intake. Psychopharmacology 172: 450-454.
5. Ahmed SH, Koob GF (2004b). Vertical shifts in dose-injection curves reflect reward allostasis, not sensitization (commentary on Zernig et al, 'Do vertical shifts in dose-response rate-relationships in operant conditioning procedures indicate 'sensitization' to 'drug wanting"). Psychopharmacology 171: 354-355.
6. Ahmed SH, Koob GF (2005). Transition to drug addiction: a negative reinforcement model based on an allostatic decrease in reward function. Psychopharmacology 180: 473-490.
7. Ahmed SH, Lin D, Koob GF, Parsons LH (2003). Escalation of cocaine self-administration does not depend on altered cocaine-induced nucleus accumbens dopamine levels. J Neurochem 86: 102-113.
8. Ahmed SH, Walker JR, Koob GF (2000). Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology 22: 413-421.
9. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, IV-TR edn. American Psychiatric Press: Washington, DC.
10. Bardin L, Kleven MS, Barret-Grevoz C, Depoortere R, Newman-Tancredi A (2006). Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 31: 1869-1879.
11. Ben-Shahar O, Moscarello JM, Ettenberg A (2006). One hour, but not six hours, of daily access to self-administered cocaine results in elevated levels of the dopamine transporter. Brain Res 1095: 148-153.
12. Ben-Shahar O, Moscarello JM, Jacob B, Roarty MP, Ettenberg A (2005). Prolonged daily exposure to i.v. cocaine results in tolerance to its stimulant effects. Pharmacol Biochem Behav 82: 411-416.
13. Bergman J, Kamien JB, Spealman RD (1990). Antagonism of cocaine self-administration by selective dopamine D(1) and D(2) antagonists. Behav Pharmacol 1: 355-363.
14. Bruins Slot LA, De Vries L, Newman-Tancredi A, Cussac D (2006). Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 534: 63-70.
15. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T et al (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381-389.
16. Clark D, Furmidge LJ, Petry N, Tong Z-Y, Ericsson M, Johnson D (1991). Behavioural profile of partial D2 dopamine receptor agonists: 1. Atypical inhibition of d-amphetamine-induced locomotor hyperactivity and stereotypy. Psychopharmacology 105: 381-392.
17. Colpaert FC (1996). System theory of pain and of opiate analgesia: no tolerance to opiates. Pharmacol Rev 48: 355-402.
18. Czoty PW, McCabe C, Nader MA (2005). Effects of the 5-HT(1A) agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on cocaine choice in cynomolgus monkeys. Behav Pharmacol 16: 187-191.
19. Depoortere RY, Li DH, Lane JD, Emmett-Oglesby MW (1993). Parameters of self-administration of cocaine in rats under a progressive-ratio schedule. Pharmacol Biochem Behav 45: 539-548.
20. Feltenstein MW, Altar CA, See RE (2006). Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry (in press).
21. Garcia-Ladona FJ, Cox BF (2003). BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction. CNS Drug Rev 9: 141-158.
22. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (1996). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn. The McGraw-Hill Co.: New York. pp 557-560.
23. Izzo E, Orsini C, Koob GF, Pulvirenti L (2001). A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule. Pharmacol Biochem Behav 68: 701-708.
24. Kitamura O, Wee S, Specio SE, Koob GF, Pulvirenti L (2006). Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology 186: 48-53.
25. Koob GF (1992). Neural mechanisms of drug reinforcement. Ann NY Acad Sci 654: 171-191.
26. Koob GF, Le Moal M (1997). Drug abuse: hedonic homeostatic dysregulation. Science 278: 52-58.
27. Li M, Budin R, Fleming AS, Kapur S (2005). Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats. Psychopharmacology 181: 600-610.
28. Lile JA, Stoops WW, Vansickel AR, Glaser PE, Hays LR, Rush CR (2005). Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Neuropsychopharmacology 30: 2103-2114.
29. Marona-Lewicka D, Nichols DE (2004). Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology 172: 415-421.
30. Morgan D, Brebner K, Lynch WJ, Roberts DC (2002). Increases in the reinforcing efficacy of cocaine after particular histories of reinforcement. Behav Pharmacol 13: 389-396.
31. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S (2006). Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31: 1854-1863.
32. O'Brien CP (1996). Drug addiction and drug abuse. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn. The McGraw-Hill: New York. pp 557-577.
33. Panlilio LV, Solinas M, Matthews SA, Goldberg SR (2006). Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats. Neuropsychopharmacology (in press).
34. Parsons LH, Smith AD, Justice Jr JB (1991). Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 9: 60-65.
35. Paterson NE, Markou A (2003). Increased motivation for self-administered cocaine after escalated cocaine intake. Neuroreport 14: 2229-2232.
36. Pulvirenti L, Koob GF (1994). Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol Sci 15: 374-379.
37. Richardson NR, Roberts DC (1996). Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66: 1-11.
38. Schwabe K, Koch M (2006). Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats. Psychopharmacology (in press).
39. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK (2003). Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28: 1730-1740.
40. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H et al (2001). Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158: 1206-1214.
41. Semba J, Watanabe A, Kito S, Toru M (1995). Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 34: 785-791.
42. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400-1411.
43. Sinha R, Fuse T, Aubin LR, O'Malley SS (2000). Psychological stress, drug-related cues and cocaine craving. Psychopharmacology 152: 140-148.
44. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85.
45. Stefanski R, Ladenheim B, Lee SH, Cadet JL, Goldberg SR (1999). Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine. Eur J Pharmacol 371: 123-135.
46. Svensson K, Ekman A, Piercey MF, HoffmannWE, Lum JT, Carlsson A (1991). Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors: a behavioral, biochemical and electrophysiological study. Naunyn-Schmiedebergs Arch Pharmacol 344: 263-274.
47. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M et al (2001a). Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158: 2015-2021.
48. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M et al (2001b). Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21: 9414-9418.
49. Volkow ND, Fowler JS, Wang GJ, Swanson JM (2004). Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 9: 557-569.
50. Weed MR, Woolverton WL, Paul IA (1998). Dopamine D1 and D2 receptor selectivities of phenyl-benzazepines in rhesus monkey striata. Eur J Pharmacol 361: 129-142.
51. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM et al (1996). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2: 699-703.
52. Woolverton WL, Johnson KM (1992). Neurobiology of cocaine abuse. Trends Pharmacol Sci 13: 193-200.
53. Zernig G, Wakonigg G, Madlung E, Haring C, Saria A (2004). Do vertical shifts in dose-response rate-relationships in operant conditioning procedures indicate 'sensitization' to 'drug wanting'? Psychopharmacology 171: 349-351.